Malvern-based Realm Therapeutics, which previously only listed its shares on the London Stock Exchange’s AIM for small companies, has started listing on NASDAQ, writes John George for the Philadelphia Business Journal.

“NASDAQ is (a) broader place that we believe will help (the company’s stock) appeal to more investors,” said Realm CEO Alex Martin.

The company will continue to list its shares on AIM, where its stock was trading at £0.39 at the end of last week.

Known as PuriCore when it was founded in London 15 years ago, Realm is now based in Chester County, where it has 15 employees focusing on drug development. Its lead drug candidate is PRO22, which is a topical gel used for treating atopic dermatitis. Around 20 million American children and adults suffer from this common type of eczema.

[uam_ad id=”71803″]

The company filed a registration statement with the Securities and Exchange Commission in late May for its proposed listing of Realm’s American Depository Shares on NASDAQ.

The SEC declared the company’s registration effective on July 4, and Realm stock currently trades under the symbol “RLM.”

Read more about Realm Therapeutics in the Philadelphia Business Journal here.

[uam_ad id=”73615″]